Absci Corporation
ABSI
Jodie situation report
Absci Corporation's move is spreading beyond its market group.
ABSI accounts for 13.3% of the group's measured movement across 9.4 effective names. raw member direction is mixed; 12 of 12 session-normalized paths align to the upside. Capital-flow agreement is 25%, so confirmation is not yet clean. No verified headline preceded the measured group move.
Is this move genuinely shared?
ABSI was the first measured mover. ABSI crossed its material path threshold at 10:15 ET. BEAM, CLYM, CRSP followed.
28 of 31 members in Biotechnology Therapeutics are active. 0 of 8 disclosed connections are confirming.
- At least 21 of 31 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- NRIX remains aligned with the group in the next market snapshot.
Invalidation: The live read weakens if participation falls to 10 of 31 members or fewer.
Who this business touches
The relationships behind ABSI
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
AMDAdvanced Micro Devices, Inc.partnerMay 7, 2026 ▾
“AMD strategic collaboration 19 In January 2025, we entered into a strategic collaboration with Advanced Micro Devices, Inc.”
ABBVAbbVie Inc.partnerMar 24, 2026 ▾
“ABS-101: There are several companies with product candidates targeting TL1A in clinical development for the treatment of IBD, including Merck’s MK-7240, Roche/Roivant’s RVT-3101, Sanofi/Teva’s TEV-48574 TL1A, Spyre’s SPY002, AbbVie’s ABBV-701, and Xencor’s Xm…”
AZNAstraZeneca PLCpartnerMar 24, 2026 ▾
“Absci has had a track record of partnerships with leading biopharmaceutical companies including Merck, AstraZeneca, Almirall and others.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 12 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
ABSI is currently a Participant in the organic co-movement group Biotechnology Therapeutics. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.